285 related articles for article (PubMed ID: 28260027)
1. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.
Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED
Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768
[TBL] [Abstract][Full Text] [Related]
3. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
4. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
5. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
6. [Our experience with detection of JAK2 mutations in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative disorders].
Burjanivová T; Marcinek J; Minárik G; Lasabová Z; Szépe P; Balhárek T; Vanochová A; Plank L
Cesk Patol; 2011 Jul; 47(3):115-7. PubMed ID: 21887928
[TBL] [Abstract][Full Text] [Related]
7. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
8. Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Guru SA; Sumi MP; Mir R; Waza AA; Bhat MA; Zuberi M; Lali P; Saxena A
Hum Cell; 2020 Oct; 33(4):1099-1111. PubMed ID: 32430672
[TBL] [Abstract][Full Text] [Related]
9. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
[TBL] [Abstract][Full Text] [Related]
10. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
[TBL] [Abstract][Full Text] [Related]
11. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
Grimwade LF; Happerfield L; Tristram C; McIntosh G; Rees M; Bench AJ; Boyd EM; Hall M; Quinn A; Piggott N; Scorer P; Scott MA; Erber WN
Br J Haematol; 2009 Nov; 147(4):495-506. PubMed ID: 19747364
[TBL] [Abstract][Full Text] [Related]
12. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
13. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
15. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
16. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
17. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
18. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.
Medves S; Noël LA; Montano-Almendras CP; Albu RI; Schoemans H; Constantinescu SN; Demoulin JB
Haematologica; 2011 Oct; 96(10):1406-14. PubMed ID: 21685469
[TBL] [Abstract][Full Text] [Related]
19. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
Koopmans SM; Schouten HC; van Marion AM
Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
